The safety of afatinib for the treatment of non-small cell lung cancer

ABSTRACT Introduction: Lung cancer tumors present EGFR mutations associated with an increased response rate to tyrosine kinase inhibitors (TKIs). Afatinib acts as an irreversible pan-ErbB-TKI. Areas covered: This review summarizes the results of clinical trials in NSCLC regarding its safety and efficacy. Expert opinion: Afatinib in 40 mg doses is highly effective in patients with NSCLC and EGFR mutations, improving progression-free survival and disease-related symptoms compared to chemotherapy. Additionally, afatinib has a better response rate and shows a small benefit in progression free survival compared to first-generation TKIs, and patients with exon 19 deletion could represent a subgroup with better prognosis and overall survival. Diarrhea, mucositis and rash are frequent adverse events induced by afatinib, these can impair quality of life and sometimes afatinib discontinuation is necessary. Management of adverse events, including early antidiarrheal treatment and prophylactic or early antibiotic management can reduce the gastrointestinal and cutaneous adverse events, respectively. Different risk factors, including malnourishment, sarcopenia, and low body surface might be associated with a higher toxicity risk, and these groups of patients could begin treatment with a low dose of afatinib followed by a close evaluation on tolerability and toxicity in order to slowly increase the dosage of afatinib.

[1]  V. Ho,et al.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Lacouture,et al.  A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  O. Arrieta,et al.  Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel , 2016, The European Journal of Health Economics.

[4]  D. Yankelevitz,et al.  The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  K. O'Byrne,et al.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.

[6]  A. Hidalgo-Miranda,et al.  Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure , 2016, Respiratory Research.

[7]  O. Arrieta,et al.  Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial , 2016, Targeted Oncology.

[8]  R. Greil,et al.  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  O. Arrieta,et al.  Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". , 2015, Lung cancer.

[10]  L. Dirix,et al.  Management of pulmonary toxicity associated with targeted anticancer therapies , 2015, Expert opinion on drug metabolism & toxicology.

[11]  You Lu,et al.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. , 2015, The Lancet. Oncology.

[12]  V. Baracos,et al.  Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. , 2015, The oncologist.

[13]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[14]  M. Nicolson,et al.  Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK , 2015, Drugs.

[15]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[16]  V. Hirsh.  Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib , 2015, BioDrugs.

[17]  O. Arrieta,et al.  Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. , 2015, Lung cancer.

[18]  Matthew Meyerson,et al.  Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[20]  G. Bepler,et al.  Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  R. Rosell,et al.  The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. , 2015, Lung cancer.

[22]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[23]  A. Mohar,et al.  Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. , 2014, Clinical nutrition.

[24]  T. Yap,et al.  Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer , 2014, Pharmacogenomics and personalized medicine.

[25]  S. Verma,et al.  Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. , 2014, Current oncology.

[26]  H. Groen,et al.  Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. , 2014, Cancer discovery.

[27]  T. Mok,et al.  Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. , 2014, Lung cancer.

[28]  S. Dacic,et al.  Present and Future Molecular Testing of Lung Carcinoma , 2014, Advances in anatomic pathology.

[29]  S. Sakashita,et al.  Genes and pathology of non-small cell lung carcinoma. , 2014, Seminars in oncology.

[30]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[31]  T. Giessmann,et al.  Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir , 2014, Clinical Drug Investigation.

[32]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Y. Ichinose,et al.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Yongmei Yin,et al.  Clinical perspective of afatinib in non-small cell lung cancer. , 2013, Lung cancer.

[35]  J. Köhler,et al.  Diarrhea associated with afatinib: an oral ErbB family blocker , 2013, Expert review of anticancer therapy.

[36]  A. Hauschild,et al.  Dermatologic adverse events associated with afatinib: an oral ErbB family blocker , 2013, Expert review of anticancer therapy.

[37]  M. Ladanyi,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[38]  Melissa L. Johnson,et al.  Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC , 2013, OncoTargets and therapy.

[39]  R. Perez-Padilla,et al.  [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[40]  M. Ladanyi,et al.  HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.

[41]  A. Cardona,et al.  Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non–Small-Cell Lung Cancer Related to Wood-Smoke Exposure , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  S. Kamel‐Reid,et al.  Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. , 2012, Current oncology.

[43]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[44]  J. Shih,et al.  Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. , 2012, The Lancet. Oncology.

[45]  R. Rosell,et al.  Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  V. Hirsh.  Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. , 2011, Current oncology.

[47]  L. Crinò,et al.  The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer , 2011, Expert review of anticancer therapy.

[48]  J. Spicer,et al.  EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 , 2010, Targeted Oncology.

[49]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Pao,et al.  Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.

[51]  Masha Kocherginsky,et al.  Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. , 2009, Oral oncology.

[52]  D. Laber,et al.  Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers , 2009, Journal of oncology.

[53]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[54]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Reck,et al.  The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC) , 2008 .

[56]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[57]  M. Schattner,et al.  NCCN Task Force Report. prevention and management of mucositis in cancer care. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[58]  Gary Clark,et al.  Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.

[59]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[60]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[62]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[63]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[64]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[68]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  W. Travis.  Pathology of lung cancer. , 2002, Clinics in chest medicine.

[71]  K. Barrett,et al.  Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells. , 1996, The American journal of physiology.

[72]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[73]  E. Esteban,et al.  Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. , 2015, Future oncology.

[74]  Jae Cheol Lee,et al.  EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation , 2014, Cancer Chemotherapy and Pharmacology.

[75]  M. Kris,et al.  Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium , 2022 .